In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Changing Fortunes in the Generics Wars

Executive Summary

Times may be a-changing for generics companies. Last month, Ivax won FDA approval for its generic version of Bristol-Myers Squibb's blockbuster cancer therapy Taxol.

You may also be interested in...



FTC Boosts Generics, Bloodies Brands

Biovail's stock plummeted recently after a sell recommendation from a highly-regarded Wall Street analyst--who's been accused of a conflict of interest for issuing it--and an FTC ruling on its alleged anti-competitive practices. The ruling, on late-listed Orange Book entries, will curtain common anti-generic strategies.

Coty’s Newest CEO Spent 20 Years At L’Oreal Before Founding ‘New-Age’ Skin-Care Firm Orveda

Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.

Showcasing Its Pandemic Response Drug Discovery, Berkeley Lights Prepares For IPO

Chief executive Eric Hobbs talks about the technology needed to accelerate antibody, cell therapy and synthetic biology, and prepare for the next pandemic.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1131437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel